We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

Back to rankings

132 hedge funds and large institutions have $278M invested in Keryx Biopharmaceuticals Inc in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 15

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

6% more funds holding

Funds holding: 125 → 132 (+7)

0% less call options, than puts

Call options by funds: $2.21M | Put options by funds: $2.22M

11% less capital invested

Capital invested by funds: $313M → $278M (-$35.3M)

Holders
132
Holders Change
+7
Holders Change %
+5.6%
% of All Funds
3.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
38
Reduced
32
Closed
15
Calls
$2.21M
Puts
$2.22M
Net Calls
-$6K
Net Calls Change
+$1.92M

Top Buyers

Rank Fund Capital Flow
1
PIMJS
PKO Investment Management Joint-Stock
Poland
+$7.16M
2
Morgan Stanley
Morgan Stanley
New York
+$3.76M
3
BlackRock
BlackRock
New York
+$2.6M
4
OWIM
Old West Investment Management
California
+$2.16M
5
RHJA
Rice Hall James & Associates
California
+$1.76M

Top Sellers

Rank Fund Capital Flow
1
CLM
ClearBridge LLC (Maryland)
Maryland
-$5.83M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.49M
3
State Street
State Street
Massachusetts
-$4.93M
4
Ameriprise
Ameriprise
Minnesota
-$3.95M
5
Goldman Sachs
Goldman Sachs
New York
-$3.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
RE
126
RBC Europe
United Kingdom
$3.57K – – –
WF
127
WealthTrust Fairport
Ohio
$3K – – –
CAC
128
Certified Advisory Corp
Florida
$2K – – –
FDCDDQ
129
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.75K – – –
FANJ
130
Financial Architects (New Jersey)
New Jersey
$1K – – –
Fidelity Investments
131
Fidelity Investments
Massachusetts
– -$5.49M -1,343,145 Closed
RPAM
132
Rhenman & Partners Asset Management
Sweden
– -$1.24M -302,157 Closed
MSU
133
Mizuho Securities USA
New York
– -$832K -203,400 Closed
STA
134
Summit Trail Advisors
New York
– -$334K -82,820 Closed
MSL
135
Mackay Shields LLC
New York
– -$294K -71,800 Closed
Squarepoint
136
Squarepoint
New York
– -$273K -66,812 Closed
Marshall Wace
137
Marshall Wace
United Kingdom
– -$244K -59,700 Closed
FWM
138
Frontier Wealth Management
Missouri
– -$174K -42,660 Closed
AQR Capital Management
139
AQR Capital Management
Connecticut
– -$115K -28,069 Closed
JT
140
Jump Trading
Illinois
– -$56K -13,746 Closed
KA
141
Kovack Advisors
Florida
– -$52K -12,600 Closed
GCP
142
GSA Capital Partners
United Kingdom
– -$42K -10,300 Closed
PCM
143
Prelude Capital Management
New York
– -$6.87K -1,411 -100%
CG
144
Cutler Group
California
– -$2K -700 Closed
Carson Wealth (CWM LLC)
145
Carson Wealth (CWM LLC)
Nebraska
– -$2K -500 Closed
GRP
146
Global Retirement Partners
California
– -$1K -240 Closed
CSS
147
Cubist Systematic Strategies
Connecticut
– +$487 +100 New
2 3 4 5
6

KERX Hedge Fund Activity: Q2 2018 in Review

132 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q2 2018, worth a combined $278M — down 11% from $313M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new KERX positions and 15 closed out — a net gain of 7 holders — while 38 added to existing stakes and 32 trimmed.

The largest buyer was PKO Investment Management Joint-Stock, opening a new position worth an estimated $7.16M. The largest seller was ClearBridge LLC (Maryland), cutting an estimated $5.83M.

  • 132 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q2 2018, up from 125 in Q1 2018.
  • Funds reported $278M of Keryx Biopharmaceuticals Inc stock for Q2 2018, down 11% quarter-over-quarter.
  • 22 funds opened new Keryx Biopharmaceuticals Inc positions in Q2 2018 and 15 closed out, a net change of +7 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q2 2018 was PKO Investment Management Joint-Stock, an estimated $7.16M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q2 2018 was ClearBridge LLC (Maryland), an estimated $5.83M sold.

Based on aggregated 13F filings for Q2 2018.